6. MannKind Corp. (MNKD, Earnings, Analysts, Financials): Focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Market cap at $803.77M, most recent closing price at $2.81.

Net institutional purchases in the current quarter at 12.7M shares, which represents about 10.17% of the company's float of 124.84M shares.

Over the last six months, insiders were net buyers of 39,997,650 shares, which represents about 32.04% of the company's 124.84M share float.

http://wire.kapitall.com/investment-idea/10-stocks-that-everyone-thinks-will-explode-higher/